Formulation: A solution in methyl acetate
Formal Name: (Z)-7-((1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl-5,5,6,6,7,7,8,8,8-d9)cyclopentyl)hept-5-enoic acid
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C20H23D9O5
Formula Weight: 361,5
Shelf life (days): 730
CAS Number: 2750534-81-5
Notes: 13,14-dihydro-15-keto-Prostaglandin E2-d9 (13,14-dihydro-15-keto PGE2-d9) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE2 (Item No. 14650) by GC- or LC-MS. 13,14-dihydro-15-keto PGE2 is a metabolite of PGE2 (Item No. 14010) and the primary PGE2 metabolite in plasma.{182,2777} It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase.{2777} Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 µM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 µM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery.{64194} Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).{64195}
English
Deutsch
